Economic Evaluation in Genomic and Precision Medicine
- 1st Edition - April 19, 2023
- Imprint: Academic Press
- Editors: Christina Mitropoulou, Sarah Wordsworth, James Buchanan, George P. Patrinos
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 3 3 8 2 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 3 3 9 4 - 1
Economic Evaluation in Genomic and Precision Medicine provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and pr… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteEconomic Evaluation in Genomic and Precision Medicine provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and precision medicine. Contributions from leading international medical geneticists and health economists compile new ways to effectively assess the costs and outcomes of different genomic care pathways, implement cost-effective medical interventions, and enhance the value of genomic and precision healthcare. Foundational chapters and discipline-specific case studies cover topics ranging from the economic analysis of genomic trial design, to health technology assessment of next-generation sequencing, ethical aspects, economic policy in genomic medicine, and pricing and reimbursement in clinical genomics.
- Introduces clinicians, researchers and students to essential concepts, protocols and applications of economic evaluation in genomic and precision medicine
- Demonstrates, through foundational chapters and discipline-specific case studies, how to assess the relative costs and outcomes of different genomic care pathways and implement cost-effective budgets
- Establishes clear precedents on how genomic technologies can be leveraged to simultaneously reduce costs and enhance the value of healthcare
- Features contributions from leading international medical geneticists and health economists that are actively evolved in economic assessments of genomic and precision medicine
Bioscientists, human geneticists, biotech industry professionals, undergraduate and graduate students in health economics and health sciences, namely medicine, pharmacy, genetics, clinicians and health managers, public health officers, health policy makers, governmental organizations, health care professionals, hospital managers
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1: Introduction to economic evaluation in health sciences
- Abstract
- 1.1: Introduction
- 1.2: Key economic concepts and terminology used in health economics
- 1.3: Economic evaluation
- 1.4: Concluding remarks
- References
- Chapter 2: Foundations of pharmacogenomics and personalized medicine
- Abstract
- Acknowledgments
- 2.1: Introduction
- 2.2: Implementing pharmacogenomics into clinical care
- 2.3: Electronic tools for translating genomic findings into a clinically meaningful format
- 2.4: Assessing the ethical, societal, and financial aspects of personalized medicine
- 2.5: Large-scale personalized medicine implementation efforts worldwide
- 2.6: Conclusions and future perspectives
- References
- Chapter 3: Economic evaluation of genome-guided treatment in oncology
- Abstract
- 3.1: Introduction
- 3.2: Methodological challenges
- 3.3: The inseparability of test and treatment
- 3.4: Value of testing
- 3.5: Cost-effectiveness comparator
- 3.6: Pricing and reimbursement
- 3.7: Conclusion
- References
- Chapter 4: Economic evaluation of rare diseases and the diagnostic odyssey
- Abstract
- Acknowledgment
- 4.1: Introduction
- 4.2: Genomics and rare diseases
- 4.3: Economic evaluations of genomics in rare diseases
- 4.4: Conclusion
- References
- Chapter 5: Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
- Abstract
- 5.1: Introduction
- 5.2: Economic evaluation of adverse drug reaction-related human leukocyte antigen genotyping, its guidelines, and current implementations
- 5.3: Conclusions
- References
- Chapter 6: Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing
- Abstract
- Acknowledgments
- 6.1: Introduction
- 6.2: Implementing personalized medicine interventions beyond high-income countries: Setting the scene
- 6.3: Examples of economic evaluations of personalized medicine interventions in medium- and low-income countries
- 6.4: A generic model as tool for measuring cost-effectiveness of personalized medicine interventions in medium- and low-income countries
- 6.5: Conclusion and future perspectives
- References
- Chapter 7: Theoretical models for economic evaluation in genomic and personalized medicine
- Abstract
- 7.1: Introduction
- 7.2: The genome economics model
- 7.3: Generalization of the genome economics model
- 7.4: Perspectives
- References
- Chapter 8: Using “big data” for economic evaluations in genomics
- Abstract
- 8.1: Introduction
- 8.2: Using “big data” for the economic evaluation of genomic tests
- 8.3: Analytics for omics data
- 8.4: Difficulties in using “big data” in for economic evaluation of sequencing tests
- 8.5: Conclusions
- References
- Further reading
- Chapter 9: Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting
- Abstract
- Acknowledgments
- 9.1: Introduction
- 9.2: Identifying stakeholders in personalized medicine
- 9.3: Eliciting and analyzing stakeholder views and opinions related to personalized medicine
- 9.4: Implementing stakeholder analysis in genomic and personalized medicine: An example from the preliminary assessment of the genomic and personalized medicine environment in Greece
- 9.5: Defining opportunities and threats when implementing genomic and personalized medicine in Greece
- 9.6: Concluding remarks
- References
- Chapter 10: Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions
- Abstract
- 10.1: Introduction
- 10.2: Institutions involved in pricing and reimbursement
- 10.3: Coverage, pricing, and reimbursement strategies for genomic testing services
- 10.4: A proposed strategy for pricing and reimbursement in personalized medicine
- 10.5: Restrictions and concerns
- 10.6: Conclusions
- References
- Index
- Edition: 1
- Published: April 19, 2023
- No. of pages (Paperback): 170
- No. of pages (eBook): 170
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128133828
- eBook ISBN: 9780128133941
CM
Christina Mitropoulou
Christina Mitropoulou is Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine. Her research interests revolve around the health economic evaluation of genome-guided therapeutic interventions. Also, Christina Mitropoulou participates as Executive Committee member of the Ubiquitous Pharmacogenomics (U-PGx) project and coordinates the health economic evaluation of the PREPARE clinical study on pre-emptive Pharmacogenomics testing, involving approx. 8000 patients from 7 clinical sites and she is an active member of the Pharmacogenomics Access and Reimbursement Coalition.
Christina Mitropoulou has published several original articles on this topic in leading scientific journals and has edited two textbooks on economic evaluation in Genomic Medicine that are published by Elsevier/Academic Press.
Affiliations and expertise
Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized MedicineSW
Sarah Wordsworth
Sarah Wordsworth is at the University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UK.
Affiliations and expertise
University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UKJB
James Buchanan
James Buchanan PhD joined the Health Economics Research Centre in 2005 and works predominantly on projects examining the economics of translating genomic high-throughput technologies from research into clinical practice, especially in cancer and infectious disease. In 2011 he was awarded a National Institute for Health Research Doctoral Research Fellowship to undertake a PhD in Health Economics investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating a targeted array in haematological cancers. Previous genomics projects include an economic evaluation of the use of genetic testing to identify the somatic mutations that can cause common cancers, an economic evaluation of the use of genetic tests to identify gastrointestinal pathogens to improve hospital infection control practice, the development of an economic modelling framework to evaluate novel genomic diagnostic tools in inflammatory bowel disease, and a cost-effectiveness analysis of microarray technology in the UK National Health Service. His other interests include costing methodology and the valuation of patient preferences. He also teaches on a range of undergraduate and postgraduate courses at the University of Oxford, and teaches advanced cost-effectiveness analysis methods to health economists and policy makers.
Affiliations and expertise
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UKGP
George P. Patrinos
Dr. George Patrinos is an Associate Professor at the University of Patras School of Health Sciences (Department of Pharmacy) in Patras, Greece with Adjunct positions in Rotterdam, the Netherlands and Al-Ain, United Arab Emirates. His research interests span the fields of molecular diagnostics, high-throughput mutation screening, the development of online mutation diagnostic tools, and the implementation of genomics into healthcare, particularly for health systems in developing countries. George Patrinos has published more than 170 scientific papers in peer reviewed journals on topics related to genetics, genomic medicine, pharmacogenomics, molecular diagnostics, and social and economic evaluation for genomic medicine. Dr. Patrinos is also the co-author of Economic Evaluation in Genomic Medicine (2015) and co-Editor of Molecular Diagnostics, Second Edition (2009), both published by Elsevier, and serves as Communicating Editor for the journal Human Mutation. Additionally, he is co-organizer of the international meeting series “Golden Helix Symposia” and “Golden Helix Pharmacogenomics Days”.
Affiliations and expertise
Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece; Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates; Zayed Center of Health Sciences, United Arab Emirates University, Al-Ain, United Arab EmiratesRead Economic Evaluation in Genomic and Precision Medicine on ScienceDirect